SCATTERED NEWS

1. Adding Velcade may increase remission rates in AML.
This was suggested in a study at Massachusetts general Hospital.
2. CD25 was a new prognosis Biomarker in Adult B-ALL.
3. Ibrutinib in combination with Rituxan is effective in CLL
420 mg PO daily with weekly 375mg/m2 of Rituxan for 4 weeks
Rituxan was then continued monthly for 6 months
RR of 83% noted.
4. Preliminary suggestions that patients taking Statins may have a reduced risk of Hepatoma.
5 Pazopanib may be no inferior to Sutent as first line therapy in Metastatic renal cell cancer.
6. Axinitib failed to meet primary end point in Metastatic Renal cell cancer.